The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Adjuvant S-1 vs. observation for resected biliary tract cancer: 5-year follow-up of the JCOG1202/ASCOT.
 
Kohei Nakachi
Honoraria - AstraZeneca; Chugai Pharma; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Pharmaceutical
 
Masafumi Ikeda
Honoraria - Abbvie; AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Eisai; Fujifilm; Guardant Health; Incyte; Lilly Japan; MSD; Nihonkayaku; Nobelpharma; Novartis; Ono Pharmaceutical; SERVIER; Taiho Pharmaceutical; Taisho Pharmaceutical Holdings; Takeda; Teijin Pharma; Yakult Pharmaceutical
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Boston Scientific; Chugai Pharma; Eisai; Guardant Health; MSD; Novartis; Roche; SERVIER
Research Funding - AstraZeneca (Inst); Bayer Yakuhin (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chiome Bioscience (Inst); Chugai Pharma (Inst); Delta-Fly Pharma (Inst); Eisai (Inst); InVitae (Inst); J-Pharma (Inst); Lilly Japan (Inst); Merck (Inst); Merus NV (Inst); MSD (Inst); Nihon Servier (Inst); Nobelpharma (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Rakuten Medical Japan (Inst); Syneos Health (Inst)
 
Masaru Konishi
No Relationships to Disclose
 
Junki Mizusawa
Employment - Pfizer (I)
Honoraria - Chugai Pharma; Taiho Pharmaceutical
 
Hiroshi Katayama
Honoraria - FUJIFILM
 
Yusuke Sano
No Relationships to Disclose
 
Katsuhiko Uesaka
No Relationships to Disclose
 
Hiroaki Yanagimoto
No Relationships to Disclose
 
Soichiro Morinaga
No Relationships to Disclose
 
Hiroshi Wada
No Relationships to Disclose
 
Kazuaki Shimada
No Relationships to Disclose
 
Yu Takahashi
No Relationships to Disclose
 
Toshio Nakagori
No Relationships to Disclose
 
Kunihito Gotoh
No Relationships to Disclose
 
Ken Kamata
No Relationships to Disclose
 
Yasuhiro Shimizu
No Relationships to Disclose
 
Hiroshi Ishii
No Relationships to Disclose
 
Takuji Okusaka
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Incyte; Kyowa Kirin International; Myriad Genetics; Nihon Servier; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - AstraZeneca; Dainippon Sumitomo Pharma; Eisai; FUJIFILM Toyama Chemistry; Nihon Servier
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chiome Bioscience; Eisai (Inst); Incyte; Syneos Health/Immunocore (Inst); Sysmex (Inst)
 
Junji Furuse
Honoraria - Astellas Pharma; AstraZeneca; Bayer Yakuhin; Chugai Pharma; Daiichi Sankyo; EA Pharma; Eisai; Fujifilm; Incyte Japan; Lilly Japan; MSD; Nihon Servier; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Teijin Pharma; Yakult Honsha
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Delta-Fly Pharma; Eisai; Fujifilm; J-Pharma; MSD; OncoTherapy Science; Ono Pharmaceutical
 
Makoto Ueno
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai; Incyte; J-pharma; MSD; Novartis; Ono Pharmaceutical; SERVIER; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Boehringer Ingelheim; Novocure
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); chio (Inst); Chiome Bioscience (Inst); Chugai Pharma (Inst); Delta-Fly Pharma (Inst); Eisai (Inst); Incyte (Inst); J-pharma (Inst); JPH Clinical Development (Inst); MSD (Inst); Novartis (Inst); Novocure (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)